Inflammation and Cardiovascular Health in Women

WHIV: Inclusion * female nascent sex * HIV * age 40-79 * self-report of stable ART for at least 180 days prior to study entry - any regimen (no more than 30 days missed medication in the last 180 days) Exclusion * self-reported history of MI, stroke, coronary revascularization * stable or unstable angina symptoms * a pre-existing diagnosis of diabetes, being actively treated with oral or injectable antihyperglycemic medication * current cocaine use * current use of exogenous oral, or transdermal, injected, or depot estrogen or testosterone * current treatment with prescription, systemic (oral, IV, or IM) steroids, or anti-inflammatory/immune suppressant medical therapies (excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDs) for autoimmune/inflammatory diseases (psoriasis, RA, IBD, lupus), post-transplant care, asthma, or pain syndromes * use of oral steroids or prescription oral anti-inflammatory/immune suppressant medication for \>7 days within the past 30 days prior to entry * pregnant or breastfeeding * eGFR \< 60 ml/min/1.73 m2 calculated by 2021 CKD-EPI Creatinine * known severe allergy to iodinated contrast media (CCTA), dextrans/DTPA/radiometals (99mTc-tilmanocept SPECT/CT), or regadenoson/adenosine (cardiac PET/CT). * self-reported significant radiation exposure (\>2 CT angiograms) received within the past 12 months * concurrent enrollment in conflicting research study. Non-HIV-infected women: As above, save for addition of inclusion criteria for negative HIV test and absent inclusion criteria for HIV and self-report of stable ART.